François Cholette, Rissa Fabia, Angela Harris, Hannah Ellis, Karla Cachero, Lukas Schroeder, Christine Mesa, Philip Lacap, Corey Arnold, Yannick Galipeau, Marc-André Langlois, Karen Colwill, Anne-Claude Gingras, Allison McGeer, Elizabeth Giles, Jacqueline Day, Carla Osiowy, Yves Durocher, Catherine Hankins, Bruce Mazer, Michael Drebot, John Kim
The extent of the COVID-19 pandemic will be better understood through serosurveys and SARS-CoV-2 antibody testing. Dried blood spot (DBS) samples will play a central role in large scale serosurveillance by simplifying biological specimen collection and transportation, especially in Canada. Direct comparative performance data on multiplex SARS-CoV-2 assays resulting from identical DBS samples are currently lacking. In our study, we aimed to provide performance data for the BioPlex 2200 SARS-CoV-2 IgG (Bio-Rad), V-PLEX SARS-CoV-2 Panel 2 IgG (MSD), and Elecsys Anti-SARS-CoV-2 (Roche) commercial assays, as well as for two highly scalable in-house assays (University of Ottawa and Mount Sinai Hospital protocols) to assess their suitability for DBS-based SARS-CoV-2 DBS serosurveillance...
September 2022: Heliyon